AI Summary & Key Takeaways
AI InsightComprehensive curettage using high-speed burr and bone graft in the treatment of chondroblastoma has good local control, low recurrence rate and excellent functional long-term result.
📌 3 Key Takeaways
Abstract
Chondroblastoma is a rare benign bone tumor that occurs at a young age and typically affects the epiphyses or apophyses of the long bones. Its treatment is curettage and adjuvant therapy. The aim of this study is to present the results of chondroblastomas that we treat as an oncology center. The information of 26 chondroblastoma patients treated in our clinic between 2009 and 2018 were retrospectively reviewed from the archive. Surgical and functional results, complications and local recurrences were analyzed. Twenty-six chondroblastoma patients, 12 females (46%) and 14 males (53%), with a mean age of 16, were followed up for 75 (37-129) months. Twenty patients (76.9%) presented with complaints of pain, while 4 patients (15.4%) presented with swelling and 2 patients (7%) with pathological fractures. The most common site was the tibia proximal in 6 patients (23.1%). Intralesional curettage + high speed burr was applied to all patients as surgical treatment. Grafts were used to fill the defect in 20 patients. Recurrence was observed in a single patient located in the proximal humerus. The mean Musculoskeletal Tumor Society (MSTS) score was 27.7±1.9. Comprehensive curettage using high-speed burr and bone graft in the treatment of chondroblastoma has good local control, low recurrence rate and excellent functional long-term result.